Branding, Immune Response and Vaccination - Clinical Research Informer

Digital innovation drives vaccine development

pharmaphorum

JANUARY 31, 2022

It is becoming increasingly important for people all over the world to understand the importance of vaccines and to have access to the vaccines they need – especially with digital innovation driving new vaccine development. Pfizer’s Josh Raysman, Saad Saeed, and Shanaya Deboo discuss vaccine awareness, access, and innovation.

Vaccination

Vaccination Vaccine Development Marketing

Keeping tabs on Covid-19: UK firm tests oral delivery of Covid-19 vaccine and Novavax aims to distribute 51 million vaccines to Australia

The Pharma Data

JANUARY 22, 2021

As research developments into RNA vaccines help scientists accelerate drug candidates to arm the immune system against coronavirus, Pharma IQ ’s Keeping tabs on Covid-19 update returns with news from some of the biotechnology innovators leading the fight against the global pandemic.

Vaccination

Vaccination Vaccine Protein Immune Response

Positive results from the first study of high-dose influenza vaccine with a COVID-19 mRNA booster support co-administration recommendations

The Pharma Data

OCTOBER 6, 2021

First study to investigate the safety and immunogenicity of both vaccines when co-administered compared to each vaccine administered separately in adults aged 65 years and older Timely new data for the start of the influenza vaccination campaigns across the Northern Hemisphere. About the study.

Vaccination

Vaccination Vaccine Licensing Licensing

Webinars

Bridging Innovation & Patient Care: The Growing Role of AI

MORE WEBINARS

Advisory Committee on Immunization Practices Recommends Pfizer’s PREVNAR 20® for Adults Previously Vaccinated with PREVNAR 13®

Pfizer

OCTOBER 20, 2022

Advisory Committee on Immunization Practices Recommends Pfizer’s PREVNAR 20® for Adults Previously Vaccinated with PREVNAR 13®. Advisory Committee on Immunization Practices Recommends Pfizer’s PREVNAR 20® for Adults Previously Vaccinated with PREVNAR 13®. Thu, 10/20/2022 - 11:33. Thursday, October 20, 2022 - 11:50am.

Vaccination

Vaccination Vaccine Containment Immune Response

U.S. FDA APPROVES TICOVAC™, PFIZER’S TICK-BORNE ENCEPHALITIS (TBE) VACCINE

The Pharma Data

AUGUST 15, 2021

Food and Drug Administration (FDA) has approved TICOVAC (tick-borne encephalitis (TBE) vaccine) for active immunization to prevent TBE in individuals 1 year of age and older. 1 TICOVAC is the only FDA-approved vaccine to help protect U.S. We are proud to deliver the first vaccine to help protect people in the U.S.

FDA Approval

FDA Approval Vaccination Vaccine Containment

FDA clears Dupixent as first drug for rare skin disorder

pharmaphorum

SEPTEMBER 29, 2022

The disorder – driven by type 2 inflammation characterised by an antibody-based immune response – causes hard lumps or nodules to form on the skin that are so itchy they can lead patients to scratch themselves to the point of bleeding or pain.

Drugs

Drugs Immune Response Allergies Sales

SELLAS Announces Promising Initial Clinical Data for Galinpepimut-S (GPS) in Combination with Checkpoint Inhibitors in Two Solid Tumor Indications

The Pharma Data

DECEMBER 20, 2020

GPS has previously been shown to invoke multi-epitope, broad cross-reactivity along the full-length of the WT1 protein, suggestive of epitope spreading, and immunologically mediated cancer cell destruction, which are hallmarks of an effective cancer vaccine. Kenilworth, N.J., a subsidiary of Merck & Co., Kenilworth, N.J.,

Life Science

Life Science Immune Response Trials Clinical Trials

Emotional empathy is driving brand equity

pharmaphorum

AUGUST 13, 2020

How the COVID-19 pandemic is forging pharmaceutical brands into better shape. Day by day it becomes clearer that some brands are coming through the pandemic in better shape than ever. These are the brands that have clearly demonstrated emotional intelligence, that have shown emotional empathy to their target audience.

Branding

Branding Vaccination Vaccine Filler

Cell-Mediated Therapies for Infectious Disease Summit

pharmaphorum

MARCH 23, 2021

In the fight against emerging coronavirus variants and spike mutations, the need for long-lasting immunity is greater than ever. This is why the time is now to look beyond antibodies and capitalize on the long-term immune response of T cell therapies. Check out the brand-new event guide here.

Immune Response

Immune Response Vaccination Vaccine Branding

BioSpace Global Roundup: Companies Slash Prices to Meet China’s Health Coverage

The Pharma Data

DECEMBER 30, 2020

Elsewhere across the globe: Arcturus Therapeutics – San Diego-based Arcturus Therapeutics received approval from the Singapore Health Sciences Authority to proceed with a Phase II clinical study of its vaccine candidate ARCT-021 against COVID-19. Surufatinib will be marketed in China under the brand name Sulanda.

Genome

Genome Genomics Immune Response Vaccination

Herd immunity won’t stop the outbreak: 3 Dangerous Covid-19 Myths

Find Me Cure

APRIL 23, 2020

Vandalizing cell towers is not going to get rid of this new virus in the corona family and avoiding certain brands of beer is not a good prevention strategy. . For Covid-19 the herd immunity threshold is 70% but this is only a rough estimate based on the current numbers we’re seeing. .

Immune Response

Immune Response Antibody Scientist Development

Transgene Announces Detailed Results From Clinical Study of TG4001 in Combination With Avelumab in Advanced HPV-positive Cancers

The Pharma Data

OCTOBER 26, 2020

In addition, the observed median PFS shows that the regimen can induce a sustained and durable response, which is also shown consistently by the induction of a specific immune response. We developed TG4001, a viral based vaccine against the HPV E6 and E7 antigens. Methods. About TG4001.

Vaccination

Vaccination Vaccine Trials Containment

Sanofi delivered close to double-digit Q4 2020

The Pharma Data

FEBRUARY 8, 2021

Vaccines up 14.6%, driven by record demand for differentiated influenza vaccines and continued growth of PPH. due to decreased sales of Cough & Cold related portfolio in Europe partially offset by Digestive Health brands. to €36,041 million, driven by Dupixent ® (€3,534 million, up 73,9%) and Vaccines. CHC down 3.0%

Sales

Sales Vaccination Vaccine Production

Sanofi delivered close to double-digit Q4 2020 business EPS(1) growth at CER

The Pharma Data

FEBRUARY 4, 2021

Vaccines up 14.6%, driven by record demand for differentiated influenza vaccines and continued growth of PPH. due to decreased sales of Cough & Cold related portfolio in Europe partially offset by Digestive Health brands. to €36,041 million, driven by Dupixent ® (€3,534 million, up 73,9%) and Vaccines. CHC down 3.0%

Sales

Sales Vaccination Vaccine Production

For Maximum Effectiveness, De-Stress and Get Healthy Before Your COVID Shot

The Pharma Data

JANUARY 22, 2021

22, 2021 — Not many people have had the opportunity to get the COVID-19 vaccine yet. But while you wait your turn, there are some steps you can take to give the vaccine — whichever brand you get — a boost when it’s available to you. This evidence is likely relevant to the COVID-19 vaccine, the researchers said.

Immune Response

Immune Response Vaccination Vaccine Antibody

Sanofi continued its growth trajectory. Strong increase in Q1 2021 business EPS(1) at CER

The Pharma Data

APRIL 27, 2021

at CER driven by growth drivers Dupixent ® and Vaccines. Vaccines up 5.3%, driven by PPH franchise and demand for influenza vaccines in southern hemisphere. due to COVID related stocking in Q1 2020 and low demand for cough and cold brands in Europe. Vaccines delivered growth in its core segments. Other vaccines.

Sales

Sales Vaccination Vaccine Medicine

Top 5 Most Promising FDA New Drug Approvals Expected in the Second Half of 2024

XTalks

MAY 2, 2024

Among these are Madrigal Pharmaceuticals’ resmetirom (branded Rezdiffra) , which secured FDA approval in March for the treatment of nonalcoholic steatohepatitis (NASH) and sotatercept (commercial name Winrevair) for pulmonary hypertension (PAH). The condition is an adverse event linked to competitor vaccines. percent to 77.8

Drugs

Drugs FDA Approval Vaccination Vaccine

Clinical Catch-Up: December 14-18 | BioSpace

The Pharma Data

DECEMBER 20, 2020

CureVac announced it has enrolled the first volunteer in the pivotal Phase IIb/III trial of its own mRNA vaccine candidate, CVnCoV against COVID-19. The technology used for the CureVac vaccine is similar to that utilized by Pfizer-BioNTech and Moderna. Russia’s Sputnik V COVID-19 vaccine demonstrated 91.4% Here’s a look.

Trials

Trials Gene Therapy Vaccination Vaccine

FDA clears Pfizer’s Prevnar 20 for adults, as Merck rival nears decision

pharmaphorum

JUNE 9, 2021

Pfizer has the FDA approval it was seeking for Prevnar 20, the latest update to its blockbuster pneumococcal vaccination franchise, keeping it one step ahead of a competing shot from Merck & Co. In two phase 3 trials in adults reported last year, V114 stimulated immune responses to all serotypes in the shot.

Vaccination

Vaccination Vaccine Immune Response Regulation

COVID-19 Pandemic Coverage

XTalks

SEPTEMBER 14, 2020

“Vaccine Nationalism” Could Prove the Undoing of COVID-19 Containment. Tension is mounting as nations big and small jockey around industry to ensure they are first in line to access a vaccine, should one prove to be successful against COVID-19. Moderna’s COVID-19 Vaccine. The price of that prize is incalculable.

Vaccination

Vaccination Vaccine Antibody Life Science

Clinical Research Informer

Digital innovation drives vaccine development

Keeping tabs on Covid-19: UK firm tests oral delivery of Covid-19 vaccine and Novavax aims to distribute 51 million vaccines to Australia

Webinars

Trending Sources

Positive results from the first study of high-dose influenza vaccine with a COVID-19 mRNA booster support co-administration recommendations

Webinars

Advisory Committee on Immunization Practices Recommends Pfizer’s PREVNAR 20® for Adults Previously Vaccinated with PREVNAR 13®

U.S. FDA APPROVES TICOVAC™, PFIZER’S TICK-BORNE ENCEPHALITIS (TBE) VACCINE

FDA clears Dupixent as first drug for rare skin disorder

SELLAS Announces Promising Initial Clinical Data for Galinpepimut-S (GPS) in Combination with Checkpoint Inhibitors in Two Solid Tumor Indications

Emotional empathy is driving brand equity

Cell-Mediated Therapies for Infectious Disease Summit

BioSpace Global Roundup: Companies Slash Prices to Meet China’s Health Coverage

Herd immunity won’t stop the outbreak: 3 Dangerous Covid-19 Myths

Transgene Announces Detailed Results From Clinical Study of TG4001 in Combination With Avelumab in Advanced HPV-positive Cancers

Sanofi delivered close to double-digit Q4 2020

Sanofi delivered close to double-digit Q4 2020 business EPS(1) growth at CER

For Maximum Effectiveness, De-Stress and Get Healthy Before Your COVID Shot

Sanofi continued its growth trajectory. Strong increase in Q1 2021 business EPS(1) at CER

Top 5 Most Promising FDA New Drug Approvals Expected in the Second Half of 2024

Clinical Catch-Up: December 14-18 | BioSpace

FDA clears Pfizer’s Prevnar 20 for adults, as Merck rival nears decision

COVID-19 Pandemic Coverage

Stay Connected